NASDAQ:VSTM Verastem (VSTM) Stock Price, News & Analysis $6.00 +0.25 (+4.35%) Closing price 07/21/2026 04:00 PM EasternExtended Trading$5.87 -0.13 (-2.13%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Verastem Stock (NASDAQ:VSTM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Verastem alerts:Sign Up Key Stats Today's Range$5.70▼$6.1050-Day Range$3.45▼$6.0352-Week Range$3.43▼$11.24Volume2.53 million shsAverage Volume3.11 million shsMarket Capitalization$527.22 millionP/E RatioN/ADividend YieldN/APrice Target$14.40Consensus RatingModerate Buy Company Overview Verastem Oncology, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapies that target cancer stemness and resistance pathways. Established in 2010 and headquartered in Needham, Massachusetts, Verastem Oncology applies a precision-medicine approach to identify key signaling nodes responsible for tumor growth and relapse, with an emphasis on hematologic malignancies and solid tumors. The company’s research platform integrates insights into complex signaling networks to advance novel compounds from early discovery through clinical proof of concept. The company’s lead marketed product is COPIKTRA (duvelisib), an oral inhibitor of PI3K-delta and PI3K-gamma, which received U.S. Food and Drug Administration approval in 2018 for the treatment of relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and follicular lymphoma. In parallel, Verastem Oncology has built a differentiated pipeline of targeted therapies, including selective Rho/MRTF pathway inhibitors and focal adhesion kinase (FAK) inhibitors, which are being evaluated in various solid tumor and blood cancer settings. Ongoing clinical trials are designed to explore monotherapy activity as well as combination regimens that may overcome resistance and improve patient outcomes. Verastem Oncology conducts its clinical and translational research activities primarily in the United States, with strategic partnerships and investigator-initiated studies extending into Europe. The company collaborates with academic institutions and industry partners to accelerate the development of its pipeline assets. Verastem Oncology’s leadership team comprises experienced drug developers and oncology specialists who are committed to advancing novel therapies that address unmet medical needs in cancer treatment. AI Generated. May Contain Errors. Read More Verastem Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScoreVSTM MarketRank™: Verastem scored higher than 63% of companies evaluated by MarketBeat, and ranked 595th out of 1,682 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingVerastem has received a consensus rating of Moderate Buy. The company's average rating score is 2.91, and is based on 2 strong buy ratings, 7 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialVerastem has a consensus price target of $14.40, representing about 140.0% upside from its current price of $6.00.Amount of Analyst CoverageVerastem has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Verastem's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Verastem are expected to grow in the coming year, from ($1.54) to ($1.09) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Verastem is -2.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Verastem is -2.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVerastem has a P/B Ratio of 8.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Verastem's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted28.02% of the float of Verastem has been sold short.Short Interest Ratio / Days to CoverVerastem has a short interest ratio ("days to cover") of 6.95.Change versus previous monthShort interest in Verastem has recently increased by 10.88%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVerastem does not currently pay a dividend.Dividend GrowthVerastem does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.32 News SentimentVerastem has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Verastem this week, compared to 4 articles on an average week.Search Interest10 people have searched for VSTM on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows5 people have added Verastem to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Verastem insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $104,333.00 in company stock.Percentage Held by Insiders1.94% of the stock of Verastem is held by insiders.Percentage Held by Institutions88.37% of the stock of Verastem is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Verastem's insider trading history. Receive VSTM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verastem and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VSTM Stock News HeadlinesVerastem’s KRAS G12D Trial Targets a New Niche in Colorectal CancerJuly 17, 2026 | tipranks.comRBC Capital Reaffirms Outperform Rating For Verastem (VSTM)July 16, 2026 | finance.yahoo.comElon says “don’t save money.” Is he right?Robert Kiyosaki, author of Rich Dad Poor Dad, says you don't have to wait for Elon Musk's vision of universal basic income. His Patriot Income Plan - funded by 14 partnerships controlling America's critical oil and gas infrastructure - already pays 10% a year with 42 payouts annually. Some investors are already collecting $4,800 a month. One has built income up to $25,000 a month. These partnerships have averaged 20% annual gains since 2020, with no U.S. tax dollars involved. The next payout drops in days. | Freedom Financial (Ad)RBC Capital Reaffirms Outperform Rating For Verastem (VSTM)July 15, 2026 | insidermonkey.comVerastem Updates Strategy for RAS/MAPK Oncology PipelineJuly 7, 2026 | theglobeandmail.comHere’s What RBC Capital Has to Say About Verastem (VSTM)July 3, 2026 | insidermonkey.comVerastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 2, 2026 | businesswire.comDaniel Calkins Sells 4,089 Shares of Verastem (NASDAQ:VSTM) StockJune 25, 2026 | insidertrades.comSee More Headlines VSTM Stock Analysis - Frequently Asked Questions How have VSTM shares performed this year? Verastem's stock was trading at $7.72 at the beginning of the year. Since then, VSTM stock has decreased by 22.3% and is now trading at $6.00. How were Verastem's earnings last quarter? Verastem, Inc. (NASDAQ:VSTM) announced its quarterly earnings results on Wednesday, March, 4th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.49) by $0.01. The biopharmaceutical company had revenue of $17.54 million for the quarter, compared to analysts' expectations of $16.85 million. Verastem had a negative trailing twelve-month return on equity of 486.40% and a negative net margin of 391.17%. Read the conference call transcript. When did Verastem's stock split? Shares of Verastem reverse split on the morning of Thursday, June 1st 2023.The 1-12 reverse split was announced on Thursday, June 1st 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. When did Verastem IPO? Verastem (VSTM) raised $45 million in an IPO on Friday, January 27th 2012. The company issued 4,500,000 shares at a price of $9.00-$11.00 per share. Who are Verastem's major shareholders? Verastem's top institutional shareholders include Hennion & Walsh Asset Management Inc. (0.65%). Insiders that own company stock include Dan Paterson, Daniel Calkins, Brian M Stuglik, Robert E Gagnon, Michael Kauffman and Paul A Bunn. View institutional ownership trends. How do I buy shares of Verastem? Shares of VSTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Verastem own? Based on aggregate information from My MarketBeat watchlists, some other companies that Verastem investors own include TherapeuticsMD (TXMD), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Micron Technology (MU) and Gilead Sciences (GILD). Company Calendar Last Earnings3/04/2026Today7/22/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (5d) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 As of 5 days ago, VSTM's financial health entered the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:VSTM CIK1526119 Webwww.verastem.com Phone(781) 292-4200FaxN/AEmployees50Year Founded2010Price Target and Rating Average Price Target for Verastem$14.40 High Price Target$18.00 Low Price Target$8.00 Potential Upside/Downside+140.0%Consensus RatingModerate Buy Rating Score (0-4)2.91 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($2.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$209.47 million Net Margins-391.17% Pretax Margin-391.17% Return on Equity-486.40% Return on Assets-91.56% Debt Debt-to-Equity Ratio0.89 Current Ratio3.04 Quick Ratio3.00 Sales & Book Value Annual Sales$30.91 million Price / Sales17.06 Cash FlowN/A Price / Cash FlowN/A Book Value$0.74 per share Price / Book8.11Miscellaneous Outstanding Shares87,870,000Free Float86,169,000Market Cap$527.22 million OptionableOptionable Beta0.29 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:VSTM) was last updated on 7/22/2026 by MarketBeat.com Staff. From Our PartnersThe options guide that actually starts at the beginningMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredElon says “don’t save money.” Is he right?Robert Kiyosaki, author of Rich Dad Poor Dad, says you don't have to wait for Elon Musk's vision of universal ...Freedom Financial | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | Sponsored30-Year market veteran reveals America’s #1 StockMarket veteran Jim Woods has flagged triple-digit gains multiple times in under two months - 151% on Netflix, ...Eagle Publishing | SponsoredForget SpaceX… this is the REAL #1 IPO of 2026While SpaceX and OpenAI dominate IPO headlines, one private company is reportedly seeing the fastest revenue g...The Oxford Club | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verastem, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verastem With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VSTM Stock Alerts